Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 13, 2026Blood Cancer Discovery

Personalized Circulating Tumor DNA Profiling Enables Superior and Universal Residual Disease Detection in Acute Myeloid Leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

RGRuwan GunaratneStanford MedicineCZCrystal M. ZhouStanford UniversitySRSanjeeth RajaramStanford Medicine

Discussion

Loading...

Member takes

Implication

Randomized trial demonstrates improved minimal residual disease detection in acute myeloid leukemia, suggesting a new standard for monitoring therapy.

Key Points

  • This research aims to enhance the detection of minimal residual disease (MRD) in acute myeloid leukemia (AML) using personalized ctDNA profiling.
  • Developed AML-CAPP-Seq, a personalized hybrid-capture assay for ciDNA assessment.
  • Analyzed longitudinal plasma and matched blood samples from 56 patients.
  • Compared plasma ctDNA detection to cellular compartment methods for MRD monitoring.
  • Plasma ctDNA predicted relapse-free survival (HR 17.8, p<0.0001) and overall survival (HR 17.0, p<0.0001) better than standard MRD methods.
  • Peri-transplant ctDNA-MRD dynamics improved relapse risk stratification in 29 allogeneic transplant recipients (HR 36.0, p=0.0009).
  • AML-CAPP-Seq showed efficacy with a median of 30.5 variants tracked per patient.

Cite This Study

Gunaratne et al. (2026) studied this question.

synapsesocial.com/papers/6a7d76792b0e0cff3f63fcedhttps://doi.org/10.1158/2643-3230.bcd-26-0159
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract 5241: Personalized fusion measurable residual disease detection in acute myeloid leukemia using droplet digital PCR2026
  2. 2Data from Early Detection of Molecular Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA2024
  3. 3Personalized and Tumor Informed Circulating Tumor DNA Assay for Molecular Residual Disease Monitoring of Solid Malignancies2025 · 3 citations
  4. 4A plasma-based test for the measurable residual disease informs the response to treatment in AML patients2025
  5. 5MRD-seq: A sensitive next generation sequencing-based approach for measurable residual disease detection in acute myeloid leukaemia2025